CFO Resigns; Internal SVP Appointed Interim CFO
IRWD has more than doubled off its 52-week low of $0.527.
Summary
Ironwood Pharmaceuticals announced the resignation of its CFO, Gregory Martini, effective May 15, 2026, and appointed Ronald Silver, SVP, Corporate Controller, as interim CFO.
Key Events · Executive and Board Changes · IRWD
-
CFO Resignation
Gregory Martini resigned from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026. The company explicitly stated his resignation was not due to any disagreement with the company on financial reporting matters.
-
Interim CFO Appointment
Ronald Silver, currently the company's Senior Vice President, Corporate Controller and Chief Accounting Officer, will serve as interim Chief Financial Officer and principal financial officer, effective May 15, 2026. Mr. Silver has been with the company since June 2018.
Analysis · IRWD · Life Sciences
The departure of a Chief Financial Officer is a significant executive change, though the company stated it was not due to disagreements over financial reporting. The appointment of an internal, experienced executive as interim CFO provides some continuity, but the change in leadership at a critical financial role warrants attention, especially following the recent disclosure of an adverse opinion on internal controls in the company's proxy statement.
At the time of this filing, IRWD was trading at $4.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.3M. The 52-week trading range was $0.53 to $5.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.